151 related articles for article (PubMed ID: 36824971)
1. Oncogenic Kras
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Sugimoto H; Arian KA; Ying H; Barekatain Y; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
bioRxiv; 2023 Feb; ():. PubMed ID: 36824971
[TBL] [Abstract][Full Text] [Related]
2. KRAS
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Paradiso F; Sugimoto H; Arian KA; Ying H; Barekatain Y; Sthanam LK; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
Cancer Cell; 2023 Sep; 41(9):1606-1620.e8. PubMed ID: 37625401
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologically targeting KRAS
Kumarasamy V; Frangou C; Wang J; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
bioRxiv; 2023 Apr; ():. PubMed ID: 37162905
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
5. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
[TBL] [Abstract][Full Text] [Related]
6. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
Wei D; Wang L; Zuo X; Maitra A; Bresalier RS
Clin Cancer Res; 2024 Feb; 30(4):655-662. PubMed ID: 37831007
[TBL] [Abstract][Full Text] [Related]
7. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8
Mahadevan KK; LeBleu VS; Ramirez EV; Chen Y; Li B; Sockwell AM; Gagea M; Sugimoto H; Sthanam LK; Tampe D; Zeisberg M; Ying H; Jain AK; DePinho RA; Maitra A; McAndrews KM; Kalluri R
Dev Cell; 2023 Sep; 58(17):1562-1577.e8. PubMed ID: 37625403
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma.
Gulay KCM; Zhang X; Pantazopoulou V; Patel J; Esparza E; Pran Babu DS; Ogawa S; Weitz J; Ng I; Mose ES; Pu M; Engle DD; Lowy AM; Tiriac H
Cancer Res; 2023 Sep; 83(18):3001-3012. PubMed ID: 37378556
[TBL] [Abstract][Full Text] [Related]
9. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
10. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
11. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.
Kemp SB; Cheng N; Markosyan N; Sor R; Kim IK; Hallin J; Shoush J; Quinones L; Brown NV; Bassett JB; Joshi N; Yuan S; Smith M; Vostrejs WP; Perez-Vale KZ; Kahn B; Mo F; Donahue TR; Radu CG; Clendenin C; Christensen JG; Vonderheide RH; Stanger BZ
Cancer Discov; 2023 Feb; 13(2):298-311. PubMed ID: 36472553
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of a small-molecule inhibitor of KRAS
Vázquez-Borrego MC; Granados-Rodríguez M; Bura FI; Martínez-López A; Rufián-Andújar B; Valenzuela-Molina F; Rodríguez-Ortiz L; Haro-Yuste S; Moreno-Serrano A; Ortega-Salas R; Pineda-Reyes R; Michán C; Alhama J; Romero-Ruiz A; Arjona-Sánchez Á
Exp Hematol Oncol; 2023 Dec; 12(1):102. PubMed ID: 38066554
[TBL] [Abstract][Full Text] [Related]
15. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
16. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
Zhang W; Nandakumar N; Shi Y; Manzano M; Smith A; Graham G; Gupta S; Vietsch EE; Laughlin SZ; Wadhwa M; Chetram M; Joshi M; Wang F; Kallakury B; Toretsky J; Wellstein A; Yi C
Sci Signal; 2014 May; 7(324):ra42. PubMed ID: 24803537
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
18. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
19. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]